Analysts Offer Insights on Healthcare Companies: Akari Therapeutics (NASDAQ: AKTX) and Catalent (NYSE: CTLT)

By Austin Angelo

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Akari Therapeutics (NASDAQ: AKTX) and Catalent (NYSE: CTLT).

Akari Therapeutics (NASDAQ: AKTX)

In a report released today, Arlinda Lee from Canaccord Genuity reiterated a Buy rating on Akari Therapeutics (NASDAQ: AKTX), with a price target of $15. The company’s shares opened today at $5.20, close to its 52-week high of $22.20.

According to TipRanks.com, Lee is a 4-star analyst with an average return of 3.9% and a 45.6% success rate. Lee covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Actinium Pharmaceuticals, and Asterias Biotherapeutics.

Akari Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $10.50.

Catalent (NYSE: CTLT)

Jefferies analyst Steven Desanctis reiterated a Hold rating on Catalent (NYSE: CTLT) today and set a price target of $32. The company’s shares opened today at $37.15, close to its 52-week high of $38.73.

According to TipRanks.com, Desanctis is a 1-star analyst with an average return of -1.1% and a 45.7% success rate. Desanctis covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Perrigo Company, and Kite Pharma Inc.

Catalent has an analyst consensus of Moderate Buy, with a price target consensus of $34.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.